Global Overactive Bladder OAB Therapeutics Market Research Report 2023(Status and Outlook)

Global Overactive Bladder OAB Therapeutics Market Research Report 2023(Status and Outlook)



Report Overview

Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.

Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.

The Global Overactive Bladder OAB Therapeutics Market Size was estimated at USD 3194.50 million in 2022 and is projected to reach USD 3569.92 million by 2029, exhibiting a CAGR of 1.60% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Overactive Bladder OAB Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Overactive Bladder OAB Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Overactive Bladder OAB Therapeutics market in any manner.

Global Overactive Bladder OAB Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Allergan

Astellas Pharma

Hisamitsu Pharmaceutical

Pfizer

Ferring

GlaxoSmithKline

Ion Channel Innovations

Kwang Dong Pharmaceutical

Lanzhou Institute of Biological Products

Merck

ONO Pharmaceutical

Sanofi

Tengion

Teva Pharmaceutical Industries

Market Segmentation (by Type)

Anticholinergic Agents

Beta-3 Adrenoreceptor Agonists

Market Segmentation (by Application)

Primary Energy Production

Refining And Recycling

Energy Conversion

Environmental Protection

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Overactive Bladder OAB Therapeutics Market

Overview of the regional outlook of the Overactive Bladder OAB Therapeutics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Overactive Bladder OAB Therapeutics
1.2 Key Market Segments
1.2.1 Overactive Bladder OAB Therapeutics Segment by Type
1.2.2 Overactive Bladder OAB Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Overactive Bladder OAB Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Overactive Bladder OAB Therapeutics Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Overactive Bladder OAB Therapeutics Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Overactive Bladder OAB Therapeutics Market Competitive Landscape
3.1 Global Overactive Bladder OAB Therapeutics Sales by Manufacturers (2018-2023)
3.2 Global Overactive Bladder OAB Therapeutics Revenue Market Share by Manufacturers (2018-2023)
3.3 Overactive Bladder OAB Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Overactive Bladder OAB Therapeutics Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Overactive Bladder OAB Therapeutics Sales Sites, Area Served, Product Type
3.6 Overactive Bladder OAB Therapeutics Market Competitive Situation and Trends
3.6.1 Overactive Bladder OAB Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Overactive Bladder OAB Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Overactive Bladder OAB Therapeutics Industry Chain Analysis
4.1 Overactive Bladder OAB Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Overactive Bladder OAB Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Overactive Bladder OAB Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Overactive Bladder OAB Therapeutics Sales Market Share by Type (2018-2023)
6.3 Global Overactive Bladder OAB Therapeutics Market Size Market Share by Type (2018-2023)
6.4 Global Overactive Bladder OAB Therapeutics Price by Type (2018-2023)
7 Overactive Bladder OAB Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Overactive Bladder OAB Therapeutics Market Sales by Application (2018-2023)
7.3 Global Overactive Bladder OAB Therapeutics Market Size (M USD) by Application (2018-2023)
7.4 Global Overactive Bladder OAB Therapeutics Sales Growth Rate by Application (2018-2023)
8 Overactive Bladder OAB Therapeutics Market Segmentation by Region
8.1 Global Overactive Bladder OAB Therapeutics Sales by Region
8.1.1 Global Overactive Bladder OAB Therapeutics Sales by Region
8.1.2 Global Overactive Bladder OAB Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Overactive Bladder OAB Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Overactive Bladder OAB Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Overactive Bladder OAB Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Overactive Bladder OAB Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Overactive Bladder OAB Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Allergan
9.1.1 Allergan Overactive Bladder OAB Therapeutics Basic Information
9.1.2 Allergan Overactive Bladder OAB Therapeutics Product Overview
9.1.3 Allergan Overactive Bladder OAB Therapeutics Product Market Performance
9.1.4 Allergan Business Overview
9.1.5 Allergan Overactive Bladder OAB Therapeutics SWOT Analysis
9.1.6 Allergan Recent Developments
9.2 Astellas Pharma
9.2.1 Astellas Pharma Overactive Bladder OAB Therapeutics Basic Information
9.2.2 Astellas Pharma Overactive Bladder OAB Therapeutics Product Overview
9.2.3 Astellas Pharma Overactive Bladder OAB Therapeutics Product Market Performance
9.2.4 Astellas Pharma Business Overview
9.2.5 Astellas Pharma Overactive Bladder OAB Therapeutics SWOT Analysis
9.2.6 Astellas Pharma Recent Developments
9.3 Hisamitsu Pharmaceutical
9.3.1 Hisamitsu Pharmaceutical Overactive Bladder OAB Therapeutics Basic Information
9.3.2 Hisamitsu Pharmaceutical Overactive Bladder OAB Therapeutics Product Overview
9.3.3 Hisamitsu Pharmaceutical Overactive Bladder OAB Therapeutics Product Market Performance
9.3.4 Hisamitsu Pharmaceutical Business Overview
9.3.5 Hisamitsu Pharmaceutical Overactive Bladder OAB Therapeutics SWOT Analysis
9.3.6 Hisamitsu Pharmaceutical Recent Developments
9.4 Pfizer
9.4.1 Pfizer Overactive Bladder OAB Therapeutics Basic Information
9.4.2 Pfizer Overactive Bladder OAB Therapeutics Product Overview
9.4.3 Pfizer Overactive Bladder OAB Therapeutics Product Market Performance
9.4.4 Pfizer Business Overview
9.4.5 Pfizer Overactive Bladder OAB Therapeutics SWOT Analysis
9.4.6 Pfizer Recent Developments
9.5 Ferring
9.5.1 Ferring Overactive Bladder OAB Therapeutics Basic Information
9.5.2 Ferring Overactive Bladder OAB Therapeutics Product Overview
9.5.3 Ferring Overactive Bladder OAB Therapeutics Product Market Performance
9.5.4 Ferring Business Overview
9.5.5 Ferring Overactive Bladder OAB Therapeutics SWOT Analysis
9.5.6 Ferring Recent Developments
9.6 GlaxoSmithKline
9.6.1 GlaxoSmithKline Overactive Bladder OAB Therapeutics Basic Information
9.6.2 GlaxoSmithKline Overactive Bladder OAB Therapeutics Product Overview
9.6.3 GlaxoSmithKline Overactive Bladder OAB Therapeutics Product Market Performance
9.6.4 GlaxoSmithKline Business Overview
9.6.5 GlaxoSmithKline Recent Developments
9.7 Ion Channel Innovations
9.7.1 Ion Channel Innovations Overactive Bladder OAB Therapeutics Basic Information
9.7.2 Ion Channel Innovations Overactive Bladder OAB Therapeutics Product Overview
9.7.3 Ion Channel Innovations Overactive Bladder OAB Therapeutics Product Market Performance
9.7.4 Ion Channel Innovations Business Overview
9.7.5 Ion Channel Innovations Recent Developments
9.8 Kwang Dong Pharmaceutical
9.8.1 Kwang Dong Pharmaceutical Overactive Bladder OAB Therapeutics Basic Information
9.8.2 Kwang Dong Pharmaceutical Overactive Bladder OAB Therapeutics Product Overview
9.8.3 Kwang Dong Pharmaceutical Overactive Bladder OAB Therapeutics Product Market Performance
9.8.4 Kwang Dong Pharmaceutical Business Overview
9.8.5 Kwang Dong Pharmaceutical Recent Developments
9.9 Lanzhou Institute of Biological Products
9.9.1 Lanzhou Institute of Biological Products Overactive Bladder OAB Therapeutics Basic Information
9.9.2 Lanzhou Institute of Biological Products Overactive Bladder OAB Therapeutics Product Overview
9.9.3 Lanzhou Institute of Biological Products Overactive Bladder OAB Therapeutics Product Market Performance
9.9.4 Lanzhou Institute of Biological Products Business Overview
9.9.5 Lanzhou Institute of Biological Products Recent Developments
9.10 Merck
9.10.1 Merck Overactive Bladder OAB Therapeutics Basic Information
9.10.2 Merck Overactive Bladder OAB Therapeutics Product Overview
9.10.3 Merck Overactive Bladder OAB Therapeutics Product Market Performance
9.10.4 Merck Business Overview
9.10.5 Merck Recent Developments
9.11 ONO Pharmaceutical
9.11.1 ONO Pharmaceutical Overactive Bladder OAB Therapeutics Basic Information
9.11.2 ONO Pharmaceutical Overactive Bladder OAB Therapeutics Product Overview
9.11.3 ONO Pharmaceutical Overactive Bladder OAB Therapeutics Product Market Performance
9.11.4 ONO Pharmaceutical Business Overview
9.11.5 ONO Pharmaceutical Recent Developments
9.12 Sanofi
9.12.1 Sanofi Overactive Bladder OAB Therapeutics Basic Information
9.12.2 Sanofi Overactive Bladder OAB Therapeutics Product Overview
9.12.3 Sanofi Overactive Bladder OAB Therapeutics Product Market Performance
9.12.4 Sanofi Business Overview
9.12.5 Sanofi Recent Developments
9.13 Tengion
9.13.1 Tengion Overactive Bladder OAB Therapeutics Basic Information
9.13.2 Tengion Overactive Bladder OAB Therapeutics Product Overview
9.13.3 Tengion Overactive Bladder OAB Therapeutics Product Market Performance
9.13.4 Tengion Business Overview
9.13.5 Tengion Recent Developments
9.14 Teva Pharmaceutical Industries
9.14.1 Teva Pharmaceutical Industries Overactive Bladder OAB Therapeutics Basic Information
9.14.2 Teva Pharmaceutical Industries Overactive Bladder OAB Therapeutics Product Overview
9.14.3 Teva Pharmaceutical Industries Overactive Bladder OAB Therapeutics Product Market Performance
9.14.4 Teva Pharmaceutical Industries Business Overview
9.14.5 Teva Pharmaceutical Industries Recent Developments
10 Overactive Bladder OAB Therapeutics Market Forecast by Region
10.1 Global Overactive Bladder OAB Therapeutics Market Size Forecast
10.2 Global Overactive Bladder OAB Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Overactive Bladder OAB Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Overactive Bladder OAB Therapeutics Market Size Forecast by Region
10.2.4 South America Overactive Bladder OAB Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Overactive Bladder OAB Therapeutics by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Overactive Bladder OAB Therapeutics Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Overactive Bladder OAB Therapeutics by Type (2024-2029)
11.1.2 Global Overactive Bladder OAB Therapeutics Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Overactive Bladder OAB Therapeutics by Type (2024-2029)
11.2 Global Overactive Bladder OAB Therapeutics Market Forecast by Application (2024-2029)
11.2.1 Global Overactive Bladder OAB Therapeutics Sales (K MT) Forecast by Application
11.2.2 Global Overactive Bladder OAB Therapeutics Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings